HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $40 price target.
June 09, 2023 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $40 price target.
The reiteration of a Buy rating and maintenance of a $40 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Annovis Bio's stock in the short term. This news is highly relevant and important for investors in ANVS, as it reflects the analyst's continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100